Skip to main content
SpringerLink
Log in

Glutamate Receptor Antagonists in the Management of Migraine

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Migraine is a neurovascular disorder that is associated with severe headache and neurologic symptoms. The pathogenesis of migraine is believed to involve trigeminovascular system activation with the primary dysfunction located in brainstem. Glutamate, the major excitatory neurotransmitter in the central nervous system, and its receptors have since long been suggested in migraine pathophysiology. Different preclinical studies have confirmed their potential role in migraine. Moreover, several glutamate receptor modulators have been studied in clinical studies, some with promising results. In this review, we will give an overview of what is known about the role of glutamate in the pathogenesis of migraine, which will be followed by an overview of available efficacy, safety and tolerability data for glutamate receptor inhibitors in clinical development for the treatment of migraine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346(4):257–70.

    Article  CAS  PubMed  Google Scholar 

  2. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009;8(7):679–90.

    Article  PubMed  Google Scholar 

  3. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol. 2000;57(3):418–20.

    Article  CAS  PubMed  Google Scholar 

  4. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(Suppl 1):1–27. doi:10.1111/j.1468-1331.2005.01202.x.

    Article  PubMed  Google Scholar 

  5. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386–98. doi:10.1038/nrn1102nrn1102.

    Article  CAS  PubMed  Google Scholar 

  6. Pollack MA, French JH. Hypothesis: glutamic acid in migraine. Headache. 1975;15(2):114–47.

    Article  CAS  PubMed  Google Scholar 

  7. Ramadan NM. Glutamate and migraine: from Ikeda to the 21st century. Cephalalgia. 2014;34(2):86–9. doi:10.1177/0333102413499646.

    Article  PubMed  Google Scholar 

  8. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol. 1989;29:365–402.

    Article  CAS  PubMed  Google Scholar 

  9. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405–96. doi:10.1124/pr.109.002451.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Busija DW, Bari F, Domoki F, Louis T. Mechanisms involved in the cerebrovascular dilator effects of N-methyl-d-aspartate in cerebral cortex. Brain Res Rev. 2007;56(1):89–100.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Bhardwaj A, Northington FJ, Ichord RN, Hanley DF, Traystman RJ, Koehler RC. Characterization of ionotropic glutamate receptor-mediated nitric oxide production in vivo in rats. Stroke. 1997;28(4):850–6.

    Article  CAS  PubMed  Google Scholar 

  12. Montana MC, Gereau RW. Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation. Curr Pharm Biotechnol. 2011;12(10):1681–8 BSP/CPB/E-Pub/000124-12-10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets. 2007;6(4):251–7.

    Article  CAS  PubMed  Google Scholar 

  14. do Carmo RJ, Martins-Ferreira H. Glutamate-K + interactions with relation to spreading cortical depression. An Acad Bras Cienc 1979;3(51):579.

  15. Gorji A, Scheller D, Straub H, Tegtmeier F, Kohling R, Hohling JM, et al. Spreading depression in human neocortical slices. Brain Res. 2001;906(1–2):74–83.

    Article  CAS  PubMed  Google Scholar 

  16. Kai-Kai MA, Howe R. Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat. Histochem J. 1991;23(4):171–9.

    Article  CAS  PubMed  Google Scholar 

  17. Xiao Y, Richter JA, Hurley JH. Release of glutamate and CGRP from trigeminal ganglion neurons: role of calcium channels and 5-HT1 receptor signaling. Mol Pain. 2008;16:4–12.

    Google Scholar 

  18. Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 2006;46(Suppl 1):S39–44.

    Article  PubMed  Google Scholar 

  19. Salt TE. Glutamate receptor functions in sensory relay in the thalamus. Philos Trans R Soc Lond B Biol Sci. 2002;357(1428):1759–66. doi:10.1098/rstb.2002.1165.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Hill RG, Salt TE. An ionophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli. J Physiol. 1982;327:65–78.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Tallaksen-Greene SJ, Young AB, Penney JB, Beitz AJ. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci Lett. 1992;141(1):79–83 0304-3940(92)90339-9.

    Article  CAS  PubMed  Google Scholar 

  22. Halpain S, Wieczorek CM, Rainbow TC. Localization of L-glutamate receptors in rat brain by quantitative autoradiography. J Neurosci. 1984;4(9):2247–58.

    CAS  PubMed  Google Scholar 

  23. Sahara Y, Noro N, Iida Y, Soma K, Nakamura Y. Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci. 1997;17(17):6611–20.

    CAS  PubMed  Google Scholar 

  24. Ferrari A, Spaccapelo L, Pinetti D, Tacchi R, Bertolini A. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia. 2009;29(4):423–9. doi:10.1111/j.1468-2982.2008.01749.x.

    Article  CAS  PubMed  Google Scholar 

  25. Vieira DS, Naffah-Mazzacoratti Mda G, Zukerman E, Senne Soares CA, Cavalheiro EA, Peres MF. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache. 2007;47(6):842–7. doi:10.1111/j.1526-4610.2007.00812.x.

  26. Baad-Hansen L, Cairns B, Ernberg M, Svensson P. Effect of systemic monosodium glutamate (MSG) on headache and pericranial muscle sensitivity. Cephalalgia. 2010;30(1):68–76. doi:10.1111/j.1468-2982.2009.01881.x.

    CAS  PubMed  Google Scholar 

  27. Shimada A, Cairns BE, Vad N, Ulriksen K, Pedersen AM, Svensson P, et al. Headache and mechanical sensitization of human pericranial muscles after repeated intake of monosodium glutamate (MSG). J Headache Pain. 2013;14(1):2. doi:10.1186/1129-2377-14-2.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47(5):614–24.

    Article  CAS  PubMed  Google Scholar 

  29. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;89(2–3):107–10 S0304395900004784.

    Article  CAS  PubMed  Google Scholar 

  30. Liang YC, Huang CC, Hsu KS. Characterization of long-term potentiation of primary afferent transmission at trigeminal synapses of juvenile rats: essential role of subtype 5 metabotropic glutamate receptors. Pain. 2005;114(3):417–28. doi:10.1016/j.pain.2005.01.008.

    Article  CAS  PubMed  Google Scholar 

  31. Jensen TS, Yaksh TL. The antinociceptive activity of excitatory amino acids in the rat brainstem: an anatomical and pharmacological analysis. Brain Res. 1992;569(2):255–67 0006-8993(92)90637-O.

    Article  CAS  PubMed  Google Scholar 

  32. Andreou A, Goadsby PJ. LY466195, a clinically active compound in the acute treatment of migraine, inhibits activation in trigeminocervical complex and ventroposteromedial thalamus after nociceptive trigeminovascular activation. Cephalalgia. 2009;29:133.

    Google Scholar 

  33. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs. 2009;18(6):789–803.

    Article  CAS  PubMed  Google Scholar 

  34. Classey JD, Knight YE, Goadsby PJ. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res. 2001;907(1–2):117–24.

    Article  CAS  PubMed  Google Scholar 

  35. Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 2000;875(1–2):119–24.

    Article  CAS  PubMed  Google Scholar 

  36. Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves N-methyl-d-aspartate and non-N-methyl-d-aspartate glutamate receptors. Neuroscience. 1999;90(4):1371–6.

    Article  CAS  PubMed  Google Scholar 

  37. Storer RJ, Goadsby PJ. N-methyl-d-aspartate receptor channel complex blockers including memantine and magnesium inhibit nociceptive traffic in the trigeminocervical complex of the rat. Cephalalgia. 2009;29 Suppl 1:135.

  38. Andreou AP, Holland PR, Goadsby PJ. Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol. 2009;157:464–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Hattori Y, Watanabe M, Iwabe T, Tanaka E, Nishi M, Aoyama J, et al. Administration of MK-801 decreases c-Fos expression in the trigeminal sensory nuclear complex but increases it in the midbrain during experimental movement of rat molars. Brain Res. 2004;1021(2):183–91. doi:10.1016/j.brainres.2004.06.048.

    Article  CAS  PubMed  Google Scholar 

  40. Mitsikostas DD, Sánchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol. 1999;127(3):623–30.

  41. Mitsikostas DD, Sánchez del Rio M, Waeber C, Moskowitz MA, Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain. 1998;76(1–2):239–48.

  42. Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, et al. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther. 2006;318(2):772–81.

    Article  CAS  PubMed  Google Scholar 

  43. Johnson KW, Dieckman DK, Phebus LA. GLUR5 antagonists as novel migraine therapies. Cephalalgia. 2001;21:268.

    Google Scholar 

  44. Lauritzen M, Hansen AJ. The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. J Cereb Blood Flow Metab. 1992;12(2):223–9.

    Article  CAS  PubMed  Google Scholar 

  45. Nellgard B, Wieloch T. NMDA-receptor blockers but not NBQX, an AMPA-receptor antagonist, inhibit spreading depression in the rat brain. Acta Physiol Scand. 1992;146(4):497–503.

    Article  CAS  PubMed  Google Scholar 

  46. Obrenovitch TP, Zilkha E. Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-methyl-d-aspartate receptor complex. Br J Pharmacol. 1996;117(5):931–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Garry MG, Walton LP, Davis MA. Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from the spinal cord is mediated by nitric oxide but not by cyclic GMP. Brain Res. 2000;861(2):208–19.

    Article  CAS  PubMed  Google Scholar 

  48. Chan KY, Vermeersch S, de Hoon J, Villalon CM, Maassenvandenbrink A. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol Ther. 2011;129(3):332–51. doi:10.1016/j.pharmthera.2010.12.001.

    Article  CAS  PubMed  Google Scholar 

  49. Chan KY, Gupta S, de Vries R, Danser AH, Villalon CM, Munoz-Islas E, et al. Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model. Br J Pharmacol. 2010;160(6):1316–25. doi:10.1111/j.1476-5381.2010.00733.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Andreou AP, Goadsby PJ. Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia. 2011;31(13):1343–58. doi:10.1177/0333102411418259.

    Article  PubMed  Google Scholar 

  51. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490–5.

    Article  PubMed  Google Scholar 

  52. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia. 2004;24(7):596–602.

    Article  CAS  PubMed  Google Scholar 

  53. Johnson KW, Nisenbaum ES, Johnson MP, Dieckman DK, Clemens-Smith A, Siuda ER. Innovative drug development for headache disorders: glutamate. In: Olesen J, Ramadan NM, editors. Frontiers in Headache Research. New York: Oxford; 2008. p. 185–94.

    Google Scholar 

  54. Gomez-Mancilla B, Brand R, Jurgens TP, Gobel H, Sommer C, Straube A, et al. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia. 2014;34(2):103–13. doi:10.1177/0333102413499648.

    Article  PubMed  Google Scholar 

  55. Goadsby PJ, Keywood C. Investigation of the role of mGluR5 inhibition in migraine: a proof of concept study of ADX10059 in acute migraine treatment. Cephalalgia. 2009;29(Suppl 1):7.

    Google Scholar 

  56. Charles A, Flippen C, Romero Reyes M, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain. 2007;8(4):248–50. doi:10.1007/s10194-007-0406-7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337–42.

    Article  PubMed  Google Scholar 

  58. Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999;288(3):960–8.

    CAS  PubMed  Google Scholar 

  59. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(Suppl 1):S52–60.

    Article  CAS  PubMed  Google Scholar 

  60. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28(3):167–79 S0920-1211(97)00045-4.

    Article  CAS  PubMed  Google Scholar 

  61. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42(2):210–20 S002839080100171X.

    Article  CAS  PubMed  Google Scholar 

  62. Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr. 2003;8(6):428–32.

    PubMed  Google Scholar 

  63. Peres MF, Mercante JP, Tanuri FC, Nunes M, Zukerman E. Chronic migraine prevention with topiramate. J Headache Pain. 2006;7(4):185–7. doi:10.1007/s10194-006-0339-6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Bartolini M, Silvestrini M, Taffi R, Lanciotti C, Luconi R, Capecci M, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol. 2005;28(6):277–9 00002826-200511000-00006.

    Article  CAS  PubMed  Google Scholar 

  65. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23(8):820–4 592.

    Article  CAS  PubMed  Google Scholar 

  66. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23. doi:10.1111/j.1468-2982.2007.01326.x.

    Article  PubMed  Google Scholar 

  67. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80. doi:10.1111/j.1526-4610.2006.00684.x.

    Article  PubMed  Google Scholar 

  68. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153–62. doi:10.1111/j.1526-4610.2009.01508.x.

    Article  PubMed  Google Scholar 

  69. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17(2):109–12.

    Article  CAS  PubMed  Google Scholar 

  70. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(Suppl 1):S16–24 hed03162.

    Article  PubMed  Google Scholar 

  71. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM; BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47(4):486–99. doi:10.1111/j.1526-4610.2006.00624.x.

  72. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007;27(6):492–503. doi:10.1111/j.1468-2982.2007.01315.x.

    Article  CAS  PubMed  Google Scholar 

  73. Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011;51(10):1573–7. doi:10.1111/j.1526-4610.2011.02022.x.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803. doi:10.1177/0333102410364676.

    Article  CAS  PubMed  Google Scholar 

  75. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14. doi:10.1177/0333102410364677.

    Article  CAS  PubMed  Google Scholar 

  76. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36. doi:10.1111/j.1526-4610.2010.01678.x.

    Article  PubMed  Google Scholar 

  77. Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77(15):1465–72. doi:10.1212/WNL.0b013e318232ab65.

    Article  CAS  PubMed  Google Scholar 

  78. Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129(1):61–70. doi:10.1111/ane.12171.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  79. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000;55(1):139–41.

    Article  CAS  PubMed  Google Scholar 

  80. Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80(7):642–7. doi:10.1212/WNL.0b013e3182824e66.

    Article  CAS  PubMed  Google Scholar 

  81. Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura: a pilot study. Cephalalgia. 1999;19(1):58–63.

    Article  CAS  PubMed  Google Scholar 

  82. D’Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia. 1999;19(1):64–6.

    Article  PubMed  Google Scholar 

  83. Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76(12):1730–2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  84. Zain S, Khan M, Alam R, Zafar I, Ahmed S. Comparison of efficacy and safety of topiramate with gabapentin in migraine prophylaxis: randomized open label control trial. J Pak Med Assoc. 2013;63(1):3–7.

    PubMed  Google Scholar 

  85. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254(5037):1515–8.

    Article  CAS  PubMed  Google Scholar 

  86. Starr MS. Antiparkinsonian actions of glutamate antagonists—alone and with l-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm Park Dis Dement Sect. 1995;10(2–3):141–85.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Kayi Chan declares that there are no conflicts of interest.

Antoinette MaassenVanDenBrink declares that there are no conflicts of interest. She was supported by the Netherlands Organization for Scientific Research (Vidi grant 917.11.349). No funding was received specifically for writing the review.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Pharmacology, Erasmus Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands

    Kayi Chan & Antoinette MaassenVanDenBrink

Authors
  1. Kayi Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoinette MaassenVanDenBrink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoinette MaassenVanDenBrink.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, K., MaassenVanDenBrink, A. Glutamate Receptor Antagonists in the Management of Migraine. Drugs 74, 1165–1176 (2014). https://doi.org/10.1007/s40265-014-0262-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0262-0

Keywords

Search

Navigation